Analyzing unmet need ahead of trial design and launch

Client Challenge

Assessing whether value perception differed across patient population segments.

A rare disease biotech company approached us to support understanding of the price potential of their asset

They were keen to understand if the value perception differed across patient population segments: highly vs moderately vs not transfusion dependent. 

P4A Solution

P4A analyzed the Anaemia landscape and perceptions of payers. We noticed fatigue, a key symptom of anaemia was:

  • extremely heterogenous
  • misunderstood
We recommended to develop a test battery with questions to assess the patients’ perceived need which can be validated in clinical trials moving forward

The Successful Outcome

The client was able to communicate the value of its asset and drive access for a broader group of patients, all in dire need of a new treatment option.

Once payers understood the burden of extreme fatigue, they were less likely to consider restricting to a transfusion dependent patient population.
The combination of medical and access professionals within P4A helped us to better communicate the unmet need and burden of disease ahead of launch.
Global Access Lead